PCSK9 and Myalgia: •Statins: hepatotoxicity, rhabdomyolysis, immune-mediated necrotizing myopathy, myalgias •Ezetimibe: hepatocellular injury, rhabdomyolysis, myopathy, myalgias, erythema multiforme, anaphylaxis, angioedema •PCSK9 inhibitors: local site reactions •Bempedoic acid: dose-related hyperuricemia, rare tendon rupture •Icosapent ethyl: increased risk of bleeding, atrial fibrillation, and atrial flutter